Drugs / HQK-1001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00717262 | May → Aug 2008 | — | HemaQuest Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00790127 | Mar 2009 → May 2010 | beta thalassemia | HemaQuest Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01322269 | Apr 2011 → Mar 2012 | sickle cell disease | HemaQuest Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HQK-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00717262 ↗ |
| Known as | 2,2-Dimethylbutyrate | “A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.” PMID 23828223 ↗ Oct 2013 |
| Action | Activate | “2,2-Dimethylbutyrate (HQK-1001), an orally-bioavailable promoter-targeted fetal globin gene-inducing agent” PMID 23828223 ↗ Oct 2013 |
| Route | Oral | “administered once a day, orally” NCT00717262 ↗ |